CellGS make progress in life science research
As Principal Consultant at Tellus Solutions, Andrew O’Dua spends most of his time supporting businesses in achieving growth. But for the rest of the time, Andrew O’Dua acts as a Business Angel – investing in a wide range of up and coming businesses. Here’s the latest news from one of them:
Cell Guidance Systems (CellGS) provide innovative life science research tools and services. They identify valuable innovations from research groups around the world and develop products that address unmet needs, providing new tools that expand the possibilities of life science research.
In the last quarter, CellGS have been making significant progress in their research and have seen the commencement of two new major projects. The first of which is a £488k venture to develop PODS proteins as a vaccine. The project, which will last a year, hopes to stabilise the issue of vaccines and may even allow the development of orally administered vaccines. In addition, CellGS sponsored PhD studentship also began in October. This studentship, at Cambridge University department of Virology will last for four years and explore the use of PODS for a norovirus vaccine.
CellGS have also recently won a government grant to examine the use of PODS growth factors to treat Osteoarthritis. They are working to develop a PODS growth factor preparation that will be injected into the synovial fluid in the joints of patients with early stages of Osteoarthritis. It is hoped that this therapy will alleviate suffering and reduce the numbers of individuals who require joint replacements. The initial studies will be completed in early 2018 and, if successful, will pave the way to clinical studies.
Andrew O’Dua takes great pride in being an investor of CellGS as he explains, “The research and studies CellGS have conducted over the past 6 years since they established have been remarkable. Their work is innovative and makes a real difference to not only the life science industry, but to people all over the world. I can’t wait to see the outcome of these research projects.”
Over the coming months, CellGS is planning to launch several new products and introduce new technologies which will have a significant impact on the field of regenerative medicine.
For more information on CellGS visit their website www.cellgs.com
